Italian prime minister invests in biotechs

Italian Prime Minister Silvio Berlusconi has burnished his reputation as someone who likes to act much younger than most 73-year-olds. Now he's backing two biotech companies that are pursuing new therapies to slow or reverse the effects of aging as well fight cancer. He now owns a large chunk of Milan-based Molecular Medicine and has invested in San Raffaele del Monte Tabor, which is building a new R&D center to study new anti-aging drugs. Report

Suggested Articles

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.